ArticleTherapeutic advances in infectious disease
Analysis of colistin resistance in carbapenem-resistant
Article in Therapeutic advances in infectious disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Global prevalence of mutation in theFrontiers in microbiology · 2024Pooled it
- Article
- Preclinical evaluation of tridecaptin M:Antimicrobial agents and chemotherapy · 2025Article
- Understanding Recent Developments in Colistin Resistance: Mechanisms, Clinical Implications, and Future Perspectives.Antibiotics (Basel, Switzerland) · 2025Review
- Determination of Colistin Resistance in Clinical Isolates from Healthcare Facilities in Mthatha and Surrounding Areas.Antibiotics (Basel, Switzerland) · 2025Article
- Colistin-Conjugated Selenium Nanoparticles: A Dual-Action Strategy Against Drug-Resistant Infections and Cancer.Pharmaceutics · 2025Article
- Regional insights on the prevalence and antimicrobial susceptibility pattern of carbapenem and colistin-resistant gram-negative bacteria: an observational cross-sectional study from Karachi, Pakistan.BMC infectious diseases · 2025Observational
- An Overview of the Genetic Mechanisms of Colistin-Resistance in Bacterial Pathogens: An Indian Perspective.Cureus · 2025Review
- Synergistic combinations of novel polymyxins and rifampicin with improved eradication of colistin-resistantBiofilm · 2024Article
- Phenotypic and molecular characterization of multidrug-resistant Enterobacterales isolated from clinical samples in Palestine: a focus on extended-spectrum β-lactamase- and carbapenemase-producing isolates.BMC infectious diseases · 2024Article
- Comparison of two commercial broth microdilution panels for multidrug-resistant Gram-negative bacteria: Thermo Scientific™ Sensititre DKMGN vs. Beckman Coulter MicroScan NMDRM1.Frontiers in microbiology · 2024Article
- A Review of Resistance to Polymyxins and Evolving Mobile Colistin Resistance Gene (Antibiotics (Basel, Switzerland) · 2023Review
- Heteroresistance to Colistin in Clinical Isolates ofAntibiotics (Basel, Switzerland) · 2023Article
- Evaluation of different methods forAccess microbiology · 2023Article
- Detection of Virulence Factors and Antibiotic Resistance amongBioMed research international · 2023Article
- Microbiologic Cure with a Simplified Dosage of Intravenous Colistin in Adults: A Retrospective Cohort Study.Infection and drug resistance · 2023Article
- Prevalence and molecular characteristics of polymyxin-resistantFrontiers in cellular and infection microbiology · 2023Article
- Global Prevalence of Colistin Resistance inPathogens (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIncreasing occurrence of infections caused by multidrug-resistant Gram-negative bacteria resulted in colistin being the last agent for treatment. Apart from plasmid-mediated METHODOLOGY: A total of 100 carbapenem-resistant
resultsAmong 100 carbapenem-resistant
conclusionsThe performance of cBMD was excellent, whereas the E-test was unacceptable. VITEK-2 and RPNP performed better but remained unreliable due to high error rates. Multiple mutations in the target proteins involving lipopolysaccharide formation, modification, and regulation were seen, resulting in colistin resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.